Clinical trial · Interventional
The Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet)
A Randomized Active-controlled Clinical Trial to Investigate the Efficacy and Safety of a Hybrid Hemostatic Device (ClearCoajet) During Endoscopic Resection for Colorectal Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The ClearCoajet is a new hemostasis device with a hybrid function (Coagulation + Injection) and is developed to provide effective coagulation, injection, and marking around lesions without changing devices during the endoscopic procedure. In this study, the investigators examine the hemostatic effect of ClearCoajet on intraprocedural bleeding during endoscopic mucosal resection or endoscopic submucosal dissection for colorectal sessile polyps or lateral growth tumors larger than 1.5 cm. The investigators also aim to compare the delayed bleeding and recurrence rates between the ClearCoajet group and the control group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colonic Polyps | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ClearCoajet | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- The ClearCoajet group
- description
- During the endoscopic resection procedures, the ClearCoajet will be used for injection and initial hemostasis for intraprocedural bleeding.
- interventionNames
- Device: ClearCoajet
- type
- ACTIVE_COMPARATOR
- label
- The control group
- description
- During the endoscopic resection procedures, the conventional injector will be used for injection.
- interventionNames
- Device: ClearCoajet
Primary outcomes (1)
- measure
- Hemostasis of intraprocedural bleeding
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * patients with colorectal sessile polyps or lateral growth tumors larger than 1.5 cm Exclusion Criteria: * Pedunculated polyp * Patients with coagulopathy
References
Publications (1)
- DERIVEDNam Y, Lee HH, Lee J, Seo SI, Kim SH, Jung Y, Cheung DY, Lee BI, Kim TO, Kim JI, Lee HS. Hemostatic Efficacy and Safety of the Hybrid Injector ClearCoajet in Endoscopic Mucosal Resection of Large Colorectal Polyps: A Multicenter Randomized Trial. Dig Dis Sci. 2026 Aug 18. doi: 10.1007/s10620-026-10163-w. Online ahead of print. PMID 42611155